STING1 and neoplasm: Moreover, advancements in nanotechnology have further enabled the development of STING agonist‐based nanotherapeutics, improving delivery and efficacy across a broader range of tumor types.[9, 44] This section reviews recent advances in combination therapies involving STING agonist‐based nanotherapeutics, with an emphasis on preclinical and clinical evidence supporting their synergistic effects.